Allostery: The Good, the Bad, and the Ugly

19Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.
Get full text

Abstract

With the advent of functional screening, more allosteric molecules are being discovered and developed as possible therapeutic entities. Allosteric proteins are unique because of two specific properties: 1) separate binding sites for allosteric modulators and guests and 2) mandatory alteration of receptor conformation upon binding of allosteric modulators. For G protein–coupled receptors, these properties produce many beneficial effects on pharmacologic systems that are described here. Allosteric discovery campaigns also bring with them added considerations that must be addressed for the endeavor to be successful, and these are described herein as well. SIGNIFICANCE STATEMENT Recent years have seen the increasing presence of allosteric molecules as possible therapeutic drug candidates. The scientific procedures to characterize these are unique and require special techniques, so it is imperative that scientists understand the new concepts involved in allosteric function. This review examines the reasons why allosteric molecules should be considered as new drug entities and the techniques required to optimize the discovery process for allosteric molecules.

Cite

CITATION STYLE

APA

Kenakin, T. (2024, January 1). Allostery: The Good, the Bad, and the Ugly. Journal of Pharmacology and Experimental Therapeutics. American Society for Pharmacology and Experimental Therapy (ASPET). https://doi.org/10.1124/jpet.123.001838

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free